The revolution of myelodysplastic syndromes

Therapeutic Advances in Hematology

Volumn 2, Issue 1, 2011, Pages 33-43

  Bejanyan, Nelli ^a   Sekeres, Mikkael A ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

ESAs; growth factors; hypomethylating agents; MDS; myelodysplastic syndromes; therapy; treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; COLONY STIMULATING FACTOR; CYTARABINE; ELTROMBOPAG; ERYTHROPOIETIN; EZATIOSTAT; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ROMIPLOSTIM;

CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OFF LABEL DRUG USE; PRIORITY JOURNAL; REVIEW;

EID: 84993682726     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620710395652     Document Type: Review

References (63)

1. Alessandrino E.P. Della Porta M.G. Bacigalupo A. Malcovati L. Angelucci E. van Lint M.T. et al (2010) Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: A GITMO study. Haematologica 95: 476–484.
2. Arber, A., Brunning, R.D., Orazi, A., Bain, B.J., Porwit, A., Vardiman, J.W. et al. (2008) Acute myeloid leukaemia with myelodysplasia-related changes, In: Swerdlow, S.H., Campo, E., Harris, N.L. (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer: Lyon, France, pp. 124–126.
3. Beran M. Shen Y. Kantarjian H. O'Brien S. Koller C.A. Giles F.J. et al (2001) High-dose chemotherapy in high-risk myelodysplastic syndrome: Covariate-adjusted comparison of five regimens. Cancer 92: 1999–2015.
4. Casadevall N. Durieux P. Dubois S. Hemery F. Lepage E. Quarre M.C. et al (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood 104: 321–327.
5. Cheson B.D. Bennett J.M. Kantarjian H. Schiffer C.A. Nimer S.D. Lowenberg B. et al (2001) Myelodysplastic syndromes standardized response criteria: Further definition. Blood 98: 1985–1995.
6. Cutler C.S. Lee S.J. Greenberg P. Deeg H.J. Perez W.S. Anasetti C. et al (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104: 579–585.
7. de Roos A.J. Deeg H.J. Onstad L. Kopecky K.J. Bowles E.J. Yong M. et al (2010) Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington State, 2005–2006. Am J Hematol 85: 765–770.
8. Ebert B.L. Pretz J. Bosco J. Chang C.Y. Tamayo P. Galili N. et al (2008) Identification of Rps 14 as a 5q-syndrome gene by RNA interference screen. Nature 451: 335–339.
9. Estey E. (2007) Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25: 1908–1915.
10. Fabre C. Grosjean J. Tailler M. Boehrer S. Ades L. Perfettini J.L. et al (2008) A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappab inhibition in malignant myeloblasts. Cell Cycle 7: 2139–2145.
11. Faderl S. Ravandi F. Huang X. Garcia-Manero G. Ferrajoli A. Estrov Z. et al (2008) A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112: 1638–1645.
12. Fenaux P. Mufti G.J. Hellstrom-Lindberg E. Santini V. Finelli C. Giagounidis A. et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10: 223–232.
13. Gabrilove, J., Paquette, R., Lyons, R.M., Mushtaq, C., Sekeres, M.A., Tomita, D. et al. (2008) Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 142 (3): 379–393.
14. Gafter-Gvili A. Fraser A. Paul M. Leibovici L. (2005) Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Int Med 142: 979–995.
15. Galili N. Cerny J. Raza A. (2007) Current treatment options: Impact of cytogenetics on the course of myelodysplasia. Curr Treat Options Oncol 8: 117–128.
16. Garcia-Manero G. Assouline S. Cortes J. Estrov Z. Kantarjian H. Yang H. et al (2008) Phase 1 study of the oral isotype specific histone deacetylase inhibitor Mgcd 0103 in leukemia. Blood 112: 981–989.
17. Golshayan A.R. Jin T. Maciejewski J. Fu A.Z. Bershadsky B. Kattan M.W. et al (2007) Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 137: 125–132.
18. Greenberg P. Cox C. Lebeau M.M. Fenaux P. Morel P. Sanz G. et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079–2088.
19. Greenberg P.L. (1998) NCCN practice guidelines for myelodyplastic syndromes. Oncology 12: 53–80.
20. Greenberg P.L. (2010) Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol 150: 131–143.
21. Greenberg P.L. Sun Z. Miller K.B. Bennett J.M. Tallman M.S. Dewald G. et al (2009) Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 114: 2393–2400.
22. Goldberg S.L. Chen E. Corral M. Guo A. Mody-Patel N. Pecora A.L. et al (2010) Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 28: 2847–2852.
23. Hellstrom-Lindberg E. Gulbrandsen N. Lindberg G. Ahlgren T. Dahl I.M. Dybedal I. et al (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 120: 1037–1046.
24. Hellstrom-Lindberg E. Negrin R. Stein R. Krantz S. Lindberg G. Vardiman J. et al (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model. Br J Haematol 99: 344–351.
25. Jadersten M. Malcovati L. Dybedal I. Della Porta M.G. Invernizzi R. Montgomery S.M. et al (2008) Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26: 3607–3613.
26. Jiang Y. Dunbar A. Gondek L.P. Mohan S. Rataul M. O'Keefe C. et al (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113: 1315–1325.
27. Kantarjian H. Fenaux P. Sekeres M.A. Becker P.S. Boruchov A. Bowen D. et al (2010) Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 28: 437–444.
28. Kantarjian H. Issa J.P. Rosenfeld C.S. Bennett J.M. Albitar M. Dipersio J. et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106: 1794–1803.
29. Kantarjian H.M. O'Brien S. Huang X. Garcia-Manero G. Ravandi F. Cortes J. et al (2007) Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: Comparison with historical experience. Cancer 109: 1133–1137.
30. Kantarjian H. O'Brien S. Ravandi F. Cortes J. Shan J. Bennett J.M. et al (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer 113: 1351–1361.
31. Kantarjian H.M. O'Brien S. Shan J. Aribi A. Garcia-Manero G. Jabbour E. et al (2007) Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109: 265–273.
32. Lim Z.Y. Killick S. Germing U. Cavenagh J. Culligan D. Bacigalupo A. et al (2007) Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 21: 1436–1441.
33. List A. Dewald G. Bennett J. Giagounidis A. Raza A. Feldman E. et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355: 1456–1465.
34. List, A., Fenaux, P., Mufti, G., Hellström-Lindberg, E., Gore, S., Bennett, J. et al. (2008) Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. ASCO Meeting Abstracts Aug 18: 7006.
35. Malcovati L. Porta M.G. Pascutto C. Invernizzi R. Boni M. Travaglino E. et al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to who criteria: A basis for clinical decision making. J Clin Oncol 23: 7594–7603.
36. Mohan, S., Fu, A., Tiu, R., Copelan, E., Saunthararajah, Y., Advani, A. et al. (2010) Prior therapy with DNA methyltransferase inhibitors (DNMTI) predicts for lower remission rates and worse survival in secondary acute myeloid leukemia patients (sAML) receiving remission induction therapy. ASH 2010, Poster Board III-812.
37. Negrin R.S. Stein R. Doherty K. Cornwell J. Vardiman J. Krantz S. et al (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87: 4076–4081.
38. Negrin R.S. Stein R. Vardiman J. Doherty K. Cornwell J. Krantz S. et al (1993) Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82: 737–743.
39. Oliansky D.M. Antin J.H. Bennett J.M. Deeg H.J. Engelhardt C. Heptinstall K.V. et al (2009) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: An evidence-based review. Biol Blood Marrow Transplant 15: 137–172.
40. Oscier D.G. (1987) Myelodysplastic syndromes. Baillieres Clin Haematol 1: 389–426.
41. Park S. Grabar S. Kelaidi C. Beyne-Rauzy O. Picard F. Bardet V. et al (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 111: 574–582.
42. Piga A. Galanello R. Forni G.L. Cappellini M.D. Origa R. Zappu A. et al (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91: 873–880.
43. Raza A. Galili N. Smith S. Godwin J. Lancet J. Melchert M. et al (2009) Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood 113: 6533–6540.
44. Raza A. Reeves J.A. Feldman E.J. Dewald G.W. Bennett J.M. Deeg H.J. et al (2008) Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111: 86–93.
45. Reuter S. Kern W. Sigge A. Döhner H. Marre R. Kern P. et al (2005) Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 40: 1087–1093.
46. Rollison D.E. Howlader N. Smith M.T. Strom S.S. Merritt W.D. Ries L.A. et al (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 112: 45–52.
47. Saunthararajah Y. Nakamura R. Nam J.M. Robyn J. Loberiza F. Maciejewski J.P. et al (2002) Hla-Dr15 (Dr2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100: 1570–1574.
48. Scott B.L. Sandmaier B.M. Storer B. Maris M.B. Sorror M.L. Maloney D.G. et al (2006) Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 20: 128–135.
49. Sekeres M.A. (2010) The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am 24: 287–294.
50. Sekeres M.A. Fu A.Z. Maciejewski J.P. Golshayan A.R. Kalaycio M.E. Kattan M.W. (2007) A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer 109: 1125–1132.
51. Sekeres M.A. Kantarjian H. Fenaux P. (2010 a) Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower-risk myelodysplastic syndromes. Cancer [Epub Ahead of Print].
52. Sekeres M.A. List A.F. Cuthbertson D. Paquette R. Ganetzky R. Latham D. et al (2010 b) Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 28: 2253–2258.
53. Sekeres M.A. Maciejewski J.P. Doneley D.W. Grinblatt D.L. Narang M. Malone J.M. (2009) A study comparing dosing regimens and efficacy of subcutaneous to intravenous azacitidine (AZA) for the treatment of myelodysplastic syndromes (MDS). Blood 114: 1460–1470.
54. Sekeres M.A. Maciejewski J.P. Giagounidis A.A. Wride K. Knight R. Raza A. et al (2008 b) Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 26: 5943–5949.
55. Sekeres, M., Narang, M., Komrokji, R., Maciejewski, J., List, A., Street, T. et al., (2010 c) Therapeutic response to azacitidine (AZA) in patients with secondary myelodysplastic syndromes (sMDS) enrolled in the AVIDA registry. ASH 2010, Poster Board II-811.
56. Sekeres M.A. Schoonen W.M. Kantarjian H. List A. Fryzek J. Paquette R. et al (2008 a) Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys. J Natl Cancer Inst 100: 1542–1551.
57. Sierra J. Perez W.S. Rozman C. Carreras E. Klein J.P. Rizzo J.D. et al (2002) Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100: 1997–2004.
58. Silverman L.R. (2009) Hypomethylating agents in myelodysplastic syndromes changing the inevitable: The value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents. Leuk Res 33(Suppl 2): S18–S21.
59. Silverman L.R. Demakos E.P. Peterson B.L. Kornblith A.B. Holland J.C. Odchimar-Reissig R. et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20: 2429–2440.
60. Sloand E.M. Mainwaring L. Fuhrer M. Ramkissoon S. Risitano A.M. Keyvanafar K. et al (2005) Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106: 841–851.
61. Steensma D.P. Baer M.R. Slack J.L. Buckstein R. Godley L.A. Garcia-Manero G. et al (2009) Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (Adopt) trial. J Clin Oncol 27: 3842–3848.
62. Wei S. Chen X. Rocha K. Epling-Burnette P.K. Djeu J.Y. Liu Q. et al (2009) A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A 106: 12974–12979.
63. Wijermans P. Suciu S. Liliana Baila L. Platzbecker U. Giagounidis A. Selleslag D. et al (2008) Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: Final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS study groups. Blood 112(Suppl.): abstr–abstr.